Document |
Document Title |
WO/2022/197528A1 |
Novel selective estrogen receptor degraders (SERDs) according to the formula: and pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof, wherein R is selected from or.
|
WO/2022/174190A1 |
Novel sophorolipid derivatives with enhanced antimicrobial activity have been identified as disinfecting active ingredients. These derivatives are produced through a fermentation of Starmerella bombicola utilizing dextrose and an oleoche...
|
WO/2022/168846A1 |
A barrier function improver which contains methylhesperidin as an active ingredient, and a barrier function improver composition which contains said barrier function improver and a pharmaceutically acceptable carrier.
|
WO/2022/151978A1 |
Provided in the present invention is a pharmaceutically active ingredient extract extracted from Polygala japonica Houtt., which extract comprises a flavonol compound of the following formula (I) structure as a first active ingredient, a...
|
WO/2022/134385A1 |
The present invention relates to the technical field of agricultural chemicals and preparation. Specifically, disclosed is a purification method for 4"-(s)-methylamino abamectin B2a benzoate. The purification method comprises the followi...
|
WO/2022/133314A1 |
Disclosed herein are enzymatic and modified host cell methods for prepared modified indole alkaloids. Also disclosed herein are modified indole alkaloids and their therapeutic use for treating diseases and disorders.
|
WO/2022/094694A1 |
Functional food comprising montbretin A and use of the functional food for limiting polysaccharide processing in a human subject and for treating conditions treatable by inhibiting pancreatic a-amylase.
|
WO/2022/089589A1 |
A flavonoid glycoside-organoamine DPP-4 inhibitor double salt. The flavonoid glycoside has the structural formula as shown in formula (1), wherein R1-R9 are independently selected from a group consisting of -H, -OH, C1-C6 alkyl, alkoxy o...
|
WO/2022/089590A1 |
The present application relates to a complex salt compound of a flavonoid glycoside and an organic amine tyrosine kinase inhibitor. The flavonoid glycoside has a general structural formula as represented by formula (1), wherein each of R...
|
WO/2022/089593A1 |
The present application relates to the technical field of pharmaceutical chemistry, and in particular relates to a double salt compound of a flavone glycoside-organic amine anti-tumor agent, a preparation method therefor and the use ther...
|
WO/2022/089600A1 |
The present application relates to a double salt compound of flavonoid glycoside and an organic amine antimicrobial agent. The flavonoid glycoside has a structural general formula represented by the following formula (1), wherein R1-R9 a...
|
WO/2022/089598A1 |
A flavonoid glycoside and organic amine neuroagonist double salt compound, a preparation method therefor, and an application thereof, a pharmaceutical composition containing a therapeutically effective amount of the double salt compound ...
|
WO/2022/079637A1 |
Analogues of oleuropein and oleacein and pharmaceutically acceptable salts thereof and processes for the preparation of these compounds are disclosed. The invention further relates to use of oleuropein and oleacein analogues for the trea...
|
WO/2022/067196A1 |
This invention is directed to compositions comprising dibenzo-alpha-pyrones (DBPs, Urolithins) and DBP glycosides, and methods of improving the immune system, providing immuno-protection, and/or treating immunosuppression in a subject wi...
|
WO/2022/052393A1 |
A method for separating and preparing paeonidin-3-O-(6-p-coumaroyl) glucoside and malvidin-3-O-(6-p-coumaroyl) glucoside. Two high-purity acylated paeonidin and malvidin anthocyanin monomers are purified and separated from grapes by mean...
|
WO/2022/052394A1 |
Disclosed in the present invention is a method for preparing a delphinidin-3-O-(6-O-p-coumaroyl) glucoside by separation. By means of steps such as extraction, macroporous resin purification, extracting, preparative liquid chromatography...
|
WO/2022/040802A1 |
Disclosed are novel glycosylated psilocybin derivative compounds that activate the 5-HT2A cell surface receptor and increase intracellular calcium concentration with a profile different from that of psilocin, and pharmaceutical and recre...
|
WO/2022/035752A1 |
Disclosed are C16 amide derivatives of C2'-epi-amphotericin B (C2'epiAmB) and salts thereof characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions, comprising any...
|
WO/2022/010252A1 |
The present invention relates to an alkylene-oxide-added polyol composition, a polyurethane using same, and a hot-melt adhesive comprising same, and, more specifically, to an alkylene oxide-added polyol composition, a polyurethane using ...
|
WO/2022/008647A1 |
Diosmin preparation method.
|
WO/2022/003181A1 |
The present invention relates to urea derivatives of polyene macrolides having the following chemical formula: wherein: - R1 is hydrogen or an alkyl or aryl or acyl group, and R2, independently of R1, is hydrogen or an alkyl or aryl or a...
|
WO/2021/263039A1 |
This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some emb...
|
WO/2021/261663A1 |
According to the present invention, provided are a benzimidazole-carbohydrate conjugate compound represented by chemical formula 1, a preparation method therefor, and a use thereof as an anticancer or antiviral agent. [Chemical formula 1...
|
WO/2021/237364A1 |
The present document describes compounds of Formula (I): or a pharmaceutically acceptable salt thereof, methods of making the same, and methods of using the same for the treatment or prevention of numerous conditions, including ulcerativ...
|
WO/2021/234200A1 |
The invention relates to a binary complex formed by an organic zinc chelate as an active agent and at least one flavonoid as a zinc ion carrier ionophore, wherein the complex is formed by the cation Zn2+ bound through four ligands to fla...
|
WO/2021/227291A1 |
Disclosed is an abamectin B2a solvated crystal, which belongs to the technical field of agricultural chemicals. By means of X-ray single crystal diffraction, it is determined that: the crystal structure is a monoclinic system; a space gr...
|
WO/2021/226002A1 |
The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compo...
|
WO/2021/201669A1 |
Disclosed herein is a polymeric amphoteric surfactant compound of formula (I).
|
WO/2021/187679A1 |
The present invention relates to a composition, comprising a sea cucumber-derived saponin compound, for preventing, alleviating, or treating neuropathy. More specifically, the sea cucumber-derived saponin compound of the present inventio...
|
WO/2021/183758A1 |
Defined herein are immunomodulating Formula (1) compounds wherein R, R0, R1, R2,R3 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The inventi...
|
WO/2021/183759A1 |
Defined herein are immunemodulating Formula (1) compounds wherein R1, R2, R3, and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention al...
|
WO/2021/183762A1 |
Defined herein are immunomodulating Formula (1) compounds stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein R0, R1, R2, R10, W, Ring C and n are as defined herein, stereoisomers thereof, and pharmaceutically a...
|
WO/2021/183754A1 |
Defined herein are immunomodulating Formula (1) compounds, wherein R1, R2 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also i...
|
WO/2021/172955A1 |
The present invention provides an intermediate useful for the synthesis of an SGLT inhibitor and a method for preparing an SGLT inhibitor using same. According to the present invention, by developing a compound of chemical formula 5 corr...
|
WO/2021/169606A1 |
Disclosed in the present invention are an avermectin B2a ethylenic derivative, and a preparation method therefor and the use thereof. The structural formula of the avermectin B2a ethylenic derivative is as represented by formula I. The c...
|
WO/2021/170621A1 |
The present invention relates to a biotechnological method for producing a C-glycoside of interest. The invention further relates to the use of a sialylated C-glycoside as a donor in an enzymatic glycosylation reaction. The present inven...
|
WO/2021/160670A1 |
The present invention relates to a 3'-ketoglycoside compound defined by formula (I) and its use for controlled release of alcohols, in particular alcohols showing an insect repellent effect. It relates also to a process for preparing the...
|
WO/2021/138847A1 |
Provided herein is macrolide compound and its use of treatment chronic respiratory disease. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers and application thereof. The compounds...
|
WO/2021/142312A1 |
Novel compositions comprising heparinoid-related compounds, manufacturing and treatment methods, kits and dosage forms thereof, are provided.
|
WO/2021/131900A1 |
The purpose of the present invention is to provide a prenylflavonoid glycoside in which two or more hexoses have been bonded to isoxanthohumol or 8-prenylnaringenin, a method for producing the same, a method for producing a prenylflavono...
|
WO/2021/122719A1 |
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.
|
WO/2021/121362A1 |
Disclosed are a furaneol glycoside compound, a pharmaceutical composition thereof, a preparation method therefor, and an application thereof. Specifically disclosed are a compound as represented by formula A-1, a pharmaceutically accepta...
|
WO/2021/113357A1 |
Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory dis...
|
WO/2021/098843A1 |
An abamectin extraction method, comprising: performing extraction on abamectin residues using a dynamic ultrasonic extraction method, and concentrating the obtained liquid extract into extractum; performing extractive desugarization on t...
|
WO/2021/081634A1 |
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...
|
WO/2021/085293A1 |
The present invention addresses the problem of providing an external skin preparation for ameliorating cellulite and a method for ameliorating cellulite, which can ameliorate cellulite in a simple manner without requiring special equipme...
|
WO/2021/075904A1 |
The present invention relates to: a newly developed triazine-based amphiphilic compound; a preparation method therefor; and a method for extracting, lysing, stabilizing, crystallizing or analyzing membrane proteins by using same. In addi...
|
WO/2021/062555A1 |
Topical formulations comprising one or more cannabinoids, one or more terpenes, and one or more flavonoids; and methods and uses thereof for the treatment of an integumentary wound, wherein the one or more cannabinoids comprise tetrahydr...
|
WO/2021/062482A1 |
The invention relates to compounds that have antiviral activity, particularly 4-oxochromane derivatives that have antiviral activity against viruses of the Family Flaviviridae. Methods of treating viruses with the 4-oxochromane compounds...
|
WO/2021/059058A1 |
A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a c...
|